New
HealthMore in Health →
Bayer Agrees to Buy Perfuse Therapeutics in $300 Million Upfront Deal
Bayer is returning to pharma dealmaking with an ophthalmology acquisition centered on a mid-stage program aimed at major causes of blindness.
Key Takeaways
- Bayer will pay $300 million upfront to acquire Perfuse Therapeutics.
- The deal centers on a mid-stage ophthalmology program.
DE
DT Editorial AI··via endpoints.news